Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study by Nambi, V. et al.
Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-
Reactive Protein Improve the Stratification of Ischemic Stroke
Risk in the Atherosclerosis Risk in Communities (ARIC) Study
Vijay Nambi, MD, Ron C. Hoogeveen, PhD, Lloyd Chambless, PhD, Yijuan Hu, Heejung Bang,
PhD, Josef Coresh, MD, PhD, Hanyu Ni, PhD, Eric Boerwinkle, PhD, Thomas Mosley, PhD,
Richey Sharrett, MD, Aaron R. Folsom, MD, and Christie M. Ballantyne, MD
From the Section of Atherosclerosis and Vascular Medicine, Department of Medicine (V.N., R.C.H.,
C.M.B.), Baylor College of Medicine, Houston, Texas; the Center for Cardiovascular Disease
Prevention (V.N., R.C.H., C.M.B.), Methodist DeBakey Heart Center, Houston, Texas; the
Department of Biostatistics (L.C., Y.H.), University of North Carolina, Chapel Hill, NC; the Division
of Biostatistics and Epidemiology, Department of Public Health (H.B.), Weill Medical College of
Cornell University, New York, NY; the Department of Epidemiology (J.C., R.S.), Johns Hopkins
Bloomberg School of Public Health, Baltimore, Md; the National Institute of Health (H.N.), Bethesda,
Md; the Human Genetics Center and Institute of Molecular Medicine (E.B.), University of Texas–
Houston Health Science Center, Houston, Texas; the Department of Medicine (T.M.), University of
Mississippi, Jackson, Miss; and the Division of Epidemiology and Community Health (A.R.F.),
University of Minnesota School of Public Health, Minneapolis, Minn
Abstract
Background and Purpose—Inflammation plays a critical role in the development of vascular
disease, and increased levels of the inflammatory biomarkers, lipoprotein-associated phospholipase
A2 (Lp-PLA2), and high-sensitivity C-reactive protein (hs-CRP) have been shown to be associated
with an increased risk for ischemic stroke.
Methods—In a prospective case– cohort (n=949) study in 12 762 apparently healthy, middle-aged
men and women in the Atherosclerosis Risk in Communities (ARIC) study, we first examined
whether Lp-PLA2 and hs-CRP levels improved the area under the receiver operator characteristic
curve (AUC) for 5-year ischemic stroke risk. We then examined how Lp-PLA2 and hs-CRP levels
altered classification of individuals into low-, intermediate-, or high-risk categories compared with
traditional risk factors.
Results—In a model using traditional risk factors alone, the AUC adjusted for optimism was 0.732,
whereas adding hs-CRP improved the AUC to 0.743, and adding Lp-PLA2 significantly improved
the AUC to 0.752. Addition of hs-CRP and Lp-PLA2 together in the model improved the AUC to
0.761, and the addition of the interaction between Lp-PLA2 and hs-CRP further significantly
improved the AUC to 0.774. With the use of traditional risk factors to assess 5-year risk for ischemic
stroke, 86% of participants were categorized as low risk (<2%); 11%, intermediate risk (2% to 5%);
and 3%, high risk (>5%). The addition of hs-CRP, Lp-PLA2, and their interaction to the model
reclassified 4%, 39%, and 34% of the low-, intermediate- and high-risk categories, respectively.
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Conclusion—Lp-PLA2 and hs-CRP may be useful in individuals classified as intermediate risk
for ischemic stroke by traditional risk factors.
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Inflammation plays a critical role in the development of atherosclerotic vascular disease.1,2
Markers associated with inflammation have been evaluated for their association with
atherosclerotic cardiovascular disease and their ability to improve cardiovascular risk
stratification. C-reactive protein (CRP) is one marker of inflammation that has been associated
with atherosclerosis, atherosclerosis-related outcomes in various vascular beds, and has been
shown to improve risk stratification for coronary heart disease (CHD).3,4 Lipoprotein-
associated phospholipase A2 (Lp-PLA2), a unique phospholipase that circulates primarily
bound to low-density lipoprotein (approximately 80%), is another marker that has been
associated with atherosclerosis and its adverse outcomes.5,6 Increased levels of Lp-PLA2 and
CRP have been associated with increased risk for stroke in the Atherosclerosis Risk in
Communities (ARIC) study.7 However, it is not known whether the addition of these
inflammatory markers improves risk assessment and risk classification for ischemic stroke in
middle-aged adults when compared with traditional risk factors (TRF).8 We examined if Lp-
PLA2±high-sensitivity (hs)-CRP improved prediction of stroke risk beyond TRF in the ARIC
study.
Materials and Methods
The ARIC study is a prospective biracial study of atherosclerotic cardiovascular disease
incidence. The study was approved by an Institutional Review Committee, and subjects gave
informed consent. In all, 15 792 individuals, initially aged 45 to 64 years, were recruited
between 1987 and 1989 from 4 communities in the United States (Forsyth County, NC, which
includes the city of Winston-Salem; northwest suburbs of Minneapolis, Minn; Washington
County, Md, which includes the city of Hagerstown; and Jackson, Miss [blacks only]). Three
other triennial examinations were conducted. A complete description of the design, objectives,
sampling strategies, and examination techniques of the ARIC study have been published
previously.9 Risk factors (cigarette smoking, blood pressure, antihypertensive medication use,
total cholesterol and high-density lipoprotein cholesterol [HDL-C] levels, and diabetes) were
measured in the ARIC study using standardized methods. Serum and plasma samples were
collected and stored at −80°C. High-sensitivity CRP and Lp-PLA2 were measured in 2003
from blood samples collected during the second visit (1990 to 1992) in a sample of the ARIC
study participants selected based on a case–cohort design.
From 12 762 apparently healthy, middle-aged men and women who participated in the second
ARIC visit and were eligible for the current analysis, we excluded individuals with prevalent
CHD, prevalent ischemic stroke, or a history of transient ischemic attack/stroke symptoms;
individuals with missing prevalence data for CHD and stroke; individuals missing information
on risk factors of interest (tobacco/smoking, diabetes, low-density lipoprotein cholesterol
[LDL-C], HDL-C, total cholesterol, systolic blood pressure, diastolic blood pressure, body
mass index, hypertension, and hypertension medication); and individuals who belonged to a
race other than “white” or “black.” Although prior ischemic stroke was an exclusion criterion
for this analysis, hemorrhagic strokes were not excluded. In all, there were 2 hemorrhagic
strokes among the individuals included for this analysis (one in each group). A case–cohort
design10,11 was then used, and 183 individuals (cases) who developed incident ischemic
stroke after Visit 2 (the baseline visit for this analysis) and before December 31, 1998 and 781
individuals from a cohort random sample (CRS) were followed for the same duration of time
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were selected after stratifying the sampling by age (>55 versus <55 years), sex, and race. The
comparison group members were randomly selected within these strata, and weighted data
analysis was conducted to provide ARIC study population estimates. The total sample size was
949 (15 cases in the CRS were excluded).
Lp-PLA2 was measured using the PLAC (diaDexus Inc, San Francisco, Calif) test, which uses
a dual monoclonal antibody immunoassay standardized to recombinant Lp-PLA2.12 hs-CRP
was measured using the Denka Seiken assay, which has been validated to the Dade Behring
method.13
Ascertainment of Stroke
For the current analysis, we included definite or probable ischemic strokes (embolic or
thrombotic). A stroke was classified as ischemic when a brain CT or MRI revealed acute
infarction or showed no evidence of hemorrhage. All definite ischemic strokes were further
classified as either lacunar or nonlacunar on the basis of the recorded neuroimaging results. Of
the 183 ischemic strokes, there were 102 definite and 81 probable strokes. Of the definite
ischemic strokes, 89 were classified as thrombotic and 13 as embolic. Only the definite,
thrombotic strokes received further classification in terms of lacunar or nonlacunar infarction,
and of the 89 definite, thrombotic strokes, 40 were classified as lacunar. Further descriptions
of stroke classification into thrombotic or embolic, definite or probable, and lacunar or
nonlacunar have been previously described.14
Incidence of stroke was found14 by contacting participants (or next of kin in the case of death)
annually to identify hospitalizations during the previous year and by surveying discharge lists
from local hospitals and death certificates from state vital statistics offices for potential
cerebrovascular events. A hospitalization was reviewed for evidence of acute stroke if the list
of discharge diagnoses included a cerebrovascular disease code (code 430 to 438 of the
International Classification of Diseases, 9th Revision),15 if a cerebrovascular condition or
procedure was mentioned in the discharge summary, or if a cerebrovascular finding was noted
on a CT or MRI report. Relevant sections of the medical record, including the type, timing,
and duration of neurological symptoms and signs, medical history, and results of relevant
diagnostic procedures (including CT and MRI of the brain), were copied and abstracted by a
single, trained nurse.
ARIC adopted the National Survey of Stroke criteria for the classification of clinical stroke.
16 The stroke criteria were translated into a computer algorithm. In addition, a physician
reviewer, blinded to the computer classification of the event, used the hospital discharge
summary and reports of neurology consultation and diagnostic procedures and classified each
potential event. Disagreements between the computer and reviewer classification were
adjudicated by a second physician reviewer.
Statistical Analysis
All statistical analyses were performed using SAS software, Version 8 (SAS Institute Inc, Cary,
NC). We examined if hs-CRP and Lp-PLA2 improved the area under the receiver operator
characteristic curve (AUC) when added to the TRF.17 The AUC estimates the probability of
the risk function assigning a higher risk probability to those who will develop an event than to
those who will not develop an event. Essentially, this statistic quantifies the ability to
discriminate events from nonevents. Receiver operator characteristic analysis is commonly
used to determine whether addition of a new risk factor to risk prediction equations provides
incremental, independent predictive power. Adding important new risk factors gives a new
prediction equation and a corresponding increase in the AUC. The level of increase can be
used to assess the value of new risk factors for discriminating events from nonevents.18 Tertiles
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were used for Lp-PLA2, whereas the cut points from the Centers for Disease Control and
Prevention/American Heart Association guidelines19 were used for hs-CRP. The AUC was
first described for the TRF (age, sex, race, current smoking, systolic blood pressure [Joint
National Committee VI blood pressure categories],20 LDL-C, HDL-C, diabetes,
antihypertensive medication, and body mass index) alone and then for TRF+hs-CRP and TRF
+Lp-PLA2, respectively. We then described the AUC when hs-CRP and Lp-PLA2 were added
together to the TRF, and finally, we described the AUC when TRF was added to hs-CRP, Lp-
PLA2, and their interaction term. The interaction term in the model is a term that allows us to
estimate how the Lp-PLA2 association with stroke varies depending on the level of hs-CRP
or, equivalently, how the hs-CRP association with stroke varies depending on the level of Lp-
PLA2. By testing the model coefficient of the term, we can test the statistical significance of
that interaction (ie, whether the variation by hs-CRP level of the size of the Lp-PLA2
association with stroke risk is statistically significant).
Bootstrapping was used to adjust for overoptimism, which occurs when the fit of a model is
tested using the same data in which the model was initially described and to furnish confidence
intervals for the differences in adjusted AUC between models with TRF and ones with the new
risk factors added.21–23
To calculate risk, a Cox proportional hazards model was applied. Specifically, the log hazard
was modeled by a linear function of traditional and novel (hs-CRP and Lp-PLA2) risk factors.
The model was fit by a SAS macro available from the Barlow macro11 that accounts for the
case–cohort design and also allows differential weighting of the strata in the cohort random
sample. This analysis and all others presented also account for the stratified random sample
nature of the CRS. These aspects of the program, therefore, allow us to make inferences to the
whole ARIC population that is at risk for incident ischemic stroke.
The risk for an individual was then taken as the predicted linear function evaluated at the given
level of his or her risk factors. Therefore, using the Cox proportional hazard models, a 5-year
risk for stroke was calculated using the TRF for each individual, and then the individual was
reclassified (using cut points that we arbitrarily chose) into low (<2% 5-year risk for stroke),
intermediate (2% to 5%), and high risk (>5%) for stroke. Then hs-CRP+Lp-PLA2 were added
to the TRF, and the 5-year stroke risk was recalculated; then individuals were classified into
various risk groups as described previously and the numbers of individuals reclassified
determined. This approach is similar to that used by Cook et al in the Women’s Health Study.
4
Subsequently, we compared the population-attributable risk (PAR) between the 2 models (ie,
TRF-alone and TRF+hs-CRP+Lp-PLA2+their interaction). To calculate the PAR for each
model, we used the estimated coefficients from the fitted Cox proportional hazards model to
calculate the 5-year probability (p*) of ischemic stroke for the group with the lowest decile of
risk and then calculated the probability (p) for the rest of the population. The percentage of
ischemic strokes that can be attributed to not being in the lowest risk group was then calculated
as 100(p−p*)/p.
Results
Baseline characteristics of the 949 individuals (183 with incident ischemic stroke [cases] and
766 from the CRS) in the study are presented in Table 1. Individuals (102 men and 81 women)
who developed incident stroke were more likely to be older; have diabetes; have higher body
mass index, systolic, diastolic blood pressure, total cholesterol, LDL-C, triglycerides, hs-CRP,
and Lp-PLA2; and have lower HDL-C than individuals in the comparison group from the CRS.
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In the TRF-alone model, the AUC for incident ischemic stroke, after bootstrapping was carried
out to adjust for the overoptimism, was 0.732. When hs-CRP was added to the model, the AUC
improved to 0.743 (95% CI for the difference, −0.0005 to 0.0183). The addition of Lp-PLA2
to the TRF-alone model, after adjustment for overoptimism, improved the AUC to 0.752 (95%
CI for the difference, 0.0028 to 0.0310). When Lp-PLA2 was added to the TRF+hs-CRP model,
the adjusted AUC improved to 0.761 (95% CI for the difference, 0.0081 to 0.0448). The
addition of the interaction term between hs-CRP and Lp-PLA2 additionally improved the
adjusted AUC to 0.774 (95% CI for the difference, 0.0182 to 0.0607; Table 2).
With the use of TRF and the ARIC stroke prediction algorithm, 86% of the participants had
<2% (low) 5-year ischemic stroke risk, 11% had a 2% to 5% (intermediate) risk, and 3% had
a >5% (high) risk, respectively. The addition of hs-CRP, Lp-PLA2, and their interaction to the
model resulted in reclassification of approximately 14% of the study population (Table 3). In
all 4.0% (approximately 32 of 815) of the individuals were reclassified from the low- to the
intermediate-risk group; 10.7% (approximately 11 of 105 individuals) and 27.9%
(approximately 29 of 105 individuals) of the individuals were reclassified from the
intermediate-risk to the high- and low-risk groups, respectively; finally, 33.3% (approximately
10 of 29 individuals) of the individuals classified as high risk were reclassified to the
intermediate-risk group. No individuals were reclassified from the low- to the high-risk group,
although 0.6% of the individuals were reclassified from the high- to the low-risk group.
Reclassification was most frequent in the intermediate-risk group. When we examined a similar
strategy using alternate cut points of risk (low=<1%, intermediate=1% to 4%, and high=>4%),
69%, 27%, and 4% were in the low-, intermediate-, and high-risk groups, respectively using
TRF alone. When hs-CRP, Lp-PLA2, and their interaction were added to this model, 6%, 35%,
and 27% of the low-, intermediate-, and high-risk groups, respectively, were reclassified.
The hs-CRP+Lp-PLA2+interaction model did better than the TRF-alone model with respect
to the PAR. For example, 90.7% of the ischemic strokes can be attributed to not being in the
lowest risk group for the TRF-only model and 94.3%, for the model with Lp-PLA2+hs-CRP
+interaction added to TRF, indicating that a greater percentage of strokes occur in the higher
risk groups when Lp-PLA2 and hs-CRP are added to the model. Similarly, the percentage PAR
for not being in the lowest 2 deciles of risk was 87.9 for the TRF-only model compared with
a percentage PAR of 90.8 for the model with Lp-PLA2+hs-CRP+interaction.
Discussion
Risk stratification and preventive therapy based on calculated (ie, low, intermediate, or high)
risk have formed the cornerstone of preventive strategies against CHD24 over the last 2 decades
with risk levels dictating the intensity of therapy (for example, target LDL-C levels). These
risk stratification tools are not perfect, and efforts have been made to improve risk stratification
by adding biomarkers and imaging to “traditional risk factors.” Although these efforts have
resulted in statistically significant improvements in risk prediction, the magnitude has been
modest and primarily in the intermediate-risk group for whom treatment decisions are often
uncertain.4,25
Although risk stratification tools for prediction of strokes such as the Framingham stroke
profile26–28 and the ARIC stroke risk score29 are available, and their use has received a Class
IA recommendation in the 2006 American Heart Association/American Stroke Association
primary prevention of stroke guidelines,30 they are not routinely used in guiding the treatment
intensity in primary prevention of stroke and do not classify individuals into risk groups. Given
that stroke is the third leading cause of death in the United States, among the leading cause for
functional impairment,31 and, like CHD, clearly preventable, tailoring therapy based on
estimated risk, like for CHD, may be useful. We examined whether such a strategy that
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classifies patients into low-, intermediate-, and high-risk groups with TRF combined with hs-
CRP and Lp-PLA2 would improve the prediction of incident ischemic stroke in the ARIC study.
C-reactive protein and Lp-PLA2 have been associated with stroke in several studies.7,32–34
Our analysis now suggests that these biomarkers modestly improve ischemic stroke risk
prediction and offer the most improvement when combined. As has been seen with the addition
of biomarkers in coronary heart disease risk prediction,4 and as is evident from Table 3, the
intermediate-risk group had the greatest reclassification with approximately 39% of the
individuals reclassified into lower or higher risk groups. Although approximately 33% of the
high-risk individuals were reclassified to a lower risk, the overall number of individuals in the
high-risk group was very small (only 3% of the total individuals in this study) and furthermore,
the majority of reclassified high-risk individuals (approximately 98%) were reclassified to the
intermediate-risk group. Given the known benefits of lifestyle modification and
pharmacotherapy in high-risk individuals (based on TRF alone), we feel that these individuals
should continue to be treated as high risk. Similarly, as expected from studies with other
biomarkers and imaging tests, very few low-risk individuals (only 4% of this group) were
reclassified, and none were reclassified into the high-risk group. We feel that from a clinical
point of view, the measurement of these biomarkers for further stratification of clinical stroke
risk should only be considered in individuals who have intermediate risk based on TRF alone
(2% to 5% 5-year stroke risk). It is interesting to note that although several individuals were
reclassified by the addition of the biomarkers, the overall number of individuals in the low-,
intermediate-, and high-risk groups remained about the same after reclassification suggesting
that biomarkers did not change the proportion of the different risk categories. We chose
somewhat arbitrary ranges (ie, <2%, 2% to 5%, and >5%, 5-year predicted risk of stroke) to
classify individuals into “low-,” “intermediate-,” and “high-risk” groups, respectively, but a
classification of <1%, 1% to 4% and >4% yielded similar results.
When examining the usefulness of a marker in improving the overall risk prediction, important
parameters to consider include improvement in the AUC of a receiver operator characteristic
and the calibration (how well the expected/predicted events correlate with the observed events).
The addition of the biomarkers increased the AUC by 0.011 for hs-CRP alone, 0.020 for Lp-
PLA2 alone, and 0.042 when hs-CRP, Lp-PLA2, and its interaction term were added even after
correcting for the overoptimism that could result from risk prediction score use and testing in
the same population. Recent papers have discussed the advantages and problems with using
the receiver operator characteristic analysis.35–38 The receiver operator characteristic analysis
is dependent on the sensitivity, specificity, and relative risk associated with the new factor and
covariation between risk factors and the new factor. Although improving the AUC should not
be a requirement for a marker to be a risk factor, it is important in risk prediction schema for
population screening. The addition of hs-CRP and Lp-PLA2 to the TRF not only improved the
AUC, but also modestly improved PAR.
Based on our analysis, the addition of both hs-CRP and Lp-PLA2 seems to satisfy the statistical
requirements for a test to improve risk prediction. However, the more important question is
whether the improvement conferred by the addition of the marker is clinically important and
cost-effective. The addition of hs-CRP and Lp-PLA2 did change risk categories in
approximately 13% of our study population. It would be ideal to validate our findings in other
cohorts, conduct studies to examine if changes in therapy secondary to such a risk stratification
scheme will improve ischemic stroke prevention, and examine cost-effectiveness of such a
strategy.
Currently, the stroke prevention guidelines recommend following the National Cholesterol
Education Program/Adult Treatment Panel III guidelines for dyslipidemia management.
Although, in most observational studies, LDL-C does not seem to be associated with the risk
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of stroke, therapy with statins has significantly reduced stroke rates.39–43 Furthermore, statins
were also recently shown to decrease the 90-day National Institutes of Health Stroke Survey
score when initiated between 3 to 9 hours postacute stroke.44 Identifying and classifying
individuals as low, intermediate, and high risk for stroke may be important in identifying
individuals who may benefit from preventive strategies such as statins and aspirin. Using the
Framingham CHD risk scores alone to determine therapy targets for dyslipidemia may miss
individuals at high risk for stroke due to the different degrees that various risk factors contribute
to stroke risk and CHD. For example, a 60-year-old nonsmoking, nondiabetic man with an
untreated systolic blood pressure of 118 mm Hg, total cholesterol of 320 mg/dL, HDL-C of 28
mg/dL, triglyceride of 250 mg/dL, and LDL-C of 242 mg/dL has a 10-year CHD risk of 22%,
whereas the 10-year stroke risk is 4%. On the other hand, a 55-year-old nonsmoking,
nondiabetic man with treated systolic blood pressure of 177 mm Hg, left ventricular
hypertrophy on his electrocardiogram, total cholesterol of 170 mg/dL, HDL-C of 60 mg/dL,
triglyceride of 200 mg/dL, and LDL-C of 70 mg/dL has a 10-year predicted CHD risk of 8%
but a stroke risk of 20%. These examples make evident how one may be at high risk for CHD
while at lower risk for stroke, and vice versa. To improve cardiovascular risk prevention, a
strategy of using both CHD and stroke risk assessment tools to calculate and classify patients
into risk groups, assessing their global vascular risk,45 and then treating individuals to the
target determined by the higher estimated risk may be required but would need careful
validation before being routinely used.
Limitations
The analysis was carried out in a case–cohort random sample of 949 individuals. The entire
ARIC cohort was not analyzed because the biomarkers were measured only in a sample of the
ARIC participants. We have not validated the new risk prediction score (ie, with the addition
of hs-CRP and Lp-PLA2) in a separate cohort. However, we did correct for the “overly
optimistic assessment,” which can occur when one fits and tests a model using the same set of
data. The blood samples were stored at −80°C for many years, which could potentially lead to
some protein degradation, but this limitation would have been the same in both the cases and
comparison group. Furthermore, the majority of studies that have examined the association of
these biomarkers with atherosclerosis have also used samples frozen for long time periods.
Summary
hs-CRP and Lp-PLA2 improved ischemic stroke risk prediction in the ARIC study. The
improvement was most enhanced when the markers were combined with the greatest benefit
in reclassification present in individuals who were intermediate risk for ischemic stroke by
traditional risk factors.
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Table 1
Baseline (Visit 2 ARIC study if not otherwise mentioned) Characteristics in Cases of Incident Ischemic Stroke and
Noncases: ARIC Study Sample
No Incident Stroke
(n=766) Incident Stroke (n=183) P Value
Age,* years 56.8 59.7 <0.0001
Men,* % 42.6 55.7 0.0001
Women,* % 57.4 44.3 0.0001
Whites,* % 75.7 56.8 <0.0001
Blacks,* % 24.3 43.2 <0.0001
Body mass index, kg/m2 28.1 28.4 0.46
Hypertension, % 32.3 58.7 <0.0001
Systolic blood pressure, mm Hg 121.4 129 <0.0001
Diastolic blood pressure, mm Hg 72.5 74.8 0.02
Diabetes, % 15.9 30.7 <0.0001
PAD, n, %† 26 (3.5%) 9 (5.0%) 0.36
Total cholesterol, mg/dL 208 212.9 0.19
LDL-C, mg/dL 131.9 136.5 0.2
HDL-C, mg/dL 50.9 47 0.001
Triglycerides, mg/dL 126 147.1 <0.001
Current tobacco use, % 19.7 33.5 <0.0001
hs-CRP, mg/L 3.08 3.8 0.01
Lp-PLA2, mg/L 0.37 0.45 <0.0001
Aspirin, %‡ 41.5 44.9 0.41
Antihypertensive medication, % 22.9 51.9 <0.001
Antilipidemic drugs, % 5.1 5.8 0.70
Statins, % 1.9 2.2 0.76
Anticoagulants 0.37 0.63 0.57
Atrial fibrillation, % 0.45 0.98 0.33
Atrial flutter, %§ 0.14 0 <0.001
*
Weighted but unadjusted, all other variables are adjusted for age, race, and gender.
†
PAD was defined as an ABI <0.9 and is based on ABI obtained in the first ARIC visit (1987 to 1989).
‡
Aspirin use was defined as taking any aspirin, Alka-Seltzer, cold medicine, or headache power in the last 2 weeks before the visit.
§
Unable to weight and adjusted for atrial flutter because there was no atrial flutter observed in the control subjects.
PAD indicates peripheral artery disease; ABI, ankle/brachial index.
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Table 2
AUC for Prediction of Ischemic Stroke With Traditional Risk Factors, CRP, and Lp-PLA2
AUC Adjusted for Optimism 95% CI for the Difference†
TRF* alone 0.732
TRF+hs-CRP 0.743 −0.0005 to 0.0183
TRF+LpPLA2 0.752 0.0028 to 0.0310
TRF+hs-CRP+LpPLA2 0.761 0.0081 to 0.0448
TRF+hs-CRP+LpPLA2+interaction 0.774 0.0182 to 0.0607
*
Age, sex, race, current smoking status, systolic blood pressure, LDL-C, HDL-C, diabetes, antihypertensive medication use, body mass index.
†
The AUC for each model was compared with the “TRF-alone” model.
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